Filing Details
- Accession Number:
- 0001104659-23-122841
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-01 16:16:44
- Reporting Period:
- 2023-11-30
- Accepted Time:
- 2023-12-01 16:16:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1017491 | Seelos Therapeutics Inc. | SEEL | Pharmaceutical Preparations (2834) | 870449967 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1639479 | Joseph Michael Golembiewski | C/O Seelos Therapeutics, Inc. 300 Park Avenue, 2Nd Floor New York NY 10022 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-11-30 | 83,000 | $1.21 | 86,450 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted average purchase price. These shares were acquired in multiple open market transactions at prices ranging from $1.07 per share to $1.27 per share, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price.
- Effective on November 28, 2023, the Issuer conducted a reverse stock split at a ratio of 1-for-30 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.
Billionaire Hedge Funds
